Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors

Therapy options for advanced pancreatic neuroendocrine tumors (pNETs) include the mTOR inhibitor everolimus and peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE, however further optimization in the therapeutic landscape is required as response rates are still low. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zellmer, Johannes, Yen, Hsi-Yu, Kaiser, Lena, Gildehaus, Franz Josef, Böning, Guido, Steiger, Katja, Hacker, Marcus, Bartenstein, Peter, Todica, Andrei, Haug, Alexander R., Ilhan, Harun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775670/
https://www.ncbi.nlm.nih.gov/pubmed/36551858
http://dx.doi.org/10.3390/biomedicines10123102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775670/
https://www.ncbi.nlm.nih.gov/pubmed/36551858
http://dx.doi.org/10.3390/biomedicines10123102

Ejemplares similares